FDA Withdraw Request for Opana Adds Another Problem to Endo’s Outlook
FDA has requested Endo withdraw Opana from the market as review of data suggests that abuse risk outweighs medical benefit of the drug. While we’ve been aware of the FDA’s concern about misuse of the product, we envisioned tighter prescribing restrictions rather than outright withdrawal following an FDA Advisory Committee meeting back in March. We're lowering our fair value estimate to $14 upon removing the drug from our model as well as reducing our outlook for some of Endo’s other products as ...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.